

<!DOCTYPE html>
<html>
<head>
    <title>全文阅读--XML全文阅读--中国知网</title>
    <link rel="icon" href="/kxreader/favicon.ico" />
    <link rel="shortcut Icon" href="/kxreader/favicon.ico" />
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
    <meta name="keywords" content="文献 XML KBASE CNKI 中国知网" />
    <meta name="description" content="XML文献检索" />
    <script type="text/javascript">
        var APPPATH = '/kxreader';
    </script>

</head>

<body>

    
<script type="text/javascript" src="//login.cnki.net/TopLogin/api/loginapi/get?type=top&amp;localCSS=&amp;returnurl=%2f%2fkns.cnki.net%2fKXReader%2fDetail%3fTIMESTAMP%3d637141641080912500%26DBCODE%3dCJFD%26TABLEName%3dCJFDLAST2019%26FileName%3dXXGK201905026%26RESULT%3d1%26SIGN%3d14kJ0Kkg7F8WoQVs%252bomroI50wDY%253d"></script>

<div id="headerBox" class="header">
    <div class="topbar">
        <div class="textalign">
            <a href="/kxreader/Detail?dbcode=CJFD&amp;filename=XXGK201905026&amp;align=md">
                <i class="icon-cen active" title="居中对齐"></i>
            </a>
            <a href="/kxreader/Detail?dbcode=CJFD&amp;filename=XXGK201905026&amp;align=lt">
                <i class="icon-left " title="左对齐"></i>
            </a>
        </div>
        <h6 class="free-tip"><i class="icon"></i>HTML阅读开放试用阶段，欢迎体验！</h6>
    </div>
</div>


    



<div class="btn-link" style="display: none"><a target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=XXGK201905026&amp;v=MTc4ODJYTVpiRzRIOWpNcW85SFlvUUtESDg0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1VSN3FmWnVabUZ5bmhWNzdOUFQ=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">知网节</a></div>

    <div class="main">

        

    <div class="sidebar-a">
        <!--sidebar start-->
        <div class="sidenav">
            <div class="arrow"><span></span></div>
            <!--sidebar_list start-->
            <dl class="sidenav-list">
                    <dt class="tit">目录结构</dt>
                            <dd class="guide">
                                    <p><a href="#50" data-title="&lt;b&gt;1 资料与方法&lt;/b&gt; "><b>1 资料与方法</b></a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#51" data-title="1.1 一般资料">1.1 一般资料</a></li>
                                                <li><a href="#53" data-title="1.2 方法">1.2 方法</a></li>
                                                <li><a href="#59" data-title="1.3 观察指标">1.3 观察指标</a></li>
                                                <li><a href="#61" data-title="1.4 统计学处理">1.4 统计学处理</a></li>
                                    </ul>
                            </dd>
                            <dd class="guide">
                                    <p><a href="#63" data-title="&lt;b&gt;2 结 果&lt;/b&gt; "><b>2 结 果</b></a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#64" data-title="2.1 两组SAQ评分比较">2.1 两组SAQ评分比较</a></li>
                                                <li><a href="#67" data-title="2.2 两组血清炎性因子水平比较">2.2 两组血清炎性因子水平比较</a></li>
                                                <li><a href="#70" data-title="2.3 两组心肌损伤指标比较">2.3 两组心肌损伤指标比较</a></li>
                                                <li><a href="#73" data-title="2.4 两组内皮功能指标比较">2.4 两组内皮功能指标比较</a></li>
                                    </ul>
                            </dd>
                            <dd class="guide">
                                    <p><a href="#76" data-title="&lt;b&gt;3 讨 论&lt;/b&gt; "><b>3 讨 论</b></a><i></i></p>
                                                            </dd>
                            <dd class="guide">
                                    <p><a href="#" data-title="文内图表 ">文内图表</a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#56" data-title="&lt;b&gt;表&lt;/b&gt;1 &lt;b&gt;两组患者一般资料比较&lt;/b&gt;"><b>表</b>1 <b>两组患者一般资料比较</b></a></li>
                                                <li><a href="#66" data-title="&lt;b&gt;表&lt;/b&gt;2 &lt;b&gt;两组&lt;/b&gt;SAQ&lt;b&gt;评分比较&lt;/b&gt;"><b>表</b>2 <b>两组</b>SAQ<b>评分比较</b></a></li>
                                                <li><a href="#69" data-title="&lt;b&gt;表&lt;/b&gt;3 &lt;b&gt;两组血清炎性因子水平比较&lt;/b&gt;&lt;mathml id=&quot;81&quot;&gt;&lt;math xmlns=&quot;http://www.w3.org/1998/Math/MathML&quot;&gt;&lt;mrow&gt;&lt;mo stretchy=&quot;false&quot;&gt;(&lt;/mo&gt;&lt;mover accent=&quot;true&quot;&gt;&lt;mi&gt;x&lt;/mi&gt;&lt;mo&gt;&#175;&lt;/mo&gt;&lt;/mover&gt;&lt;mo&gt;&#177;&lt;/mo&gt;&lt;mi&gt;s&lt;/mi&gt;&lt;mo stretchy=&quot;false&quot;&gt;)&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/mathml&gt;"><b>表</b>3 <b>两组血清炎性因子水平比较</b><mathml id="81"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mo stretchy="false">(</mo><mover accent="true"><mi>x</mi><mo>¯</mo></mover><mo>±</mo><mi>s</mi><mo stretchy="false">)</mo></mrow></math></mathml></a></li>
                                                <li><a href="#72" data-title="&lt;b&gt;表&lt;/b&gt;4 &lt;b&gt;两组心肌损伤指标比较&lt;/b&gt;&lt;mathml id=&quot;82&quot;&gt;&lt;math xmlns=&quot;http://www.w3.org/1998/Math/MathML&quot;&gt;&lt;mrow&gt;&lt;mo stretchy=&quot;false&quot;&gt;(&lt;/mo&gt;&lt;mover accent=&quot;true&quot;&gt;&lt;mi&gt;x&lt;/mi&gt;&lt;mo&gt;&#175;&lt;/mo&gt;&lt;/mover&gt;&lt;mo&gt;&#177;&lt;/mo&gt;&lt;mi&gt;s&lt;/mi&gt;&lt;mo stretchy=&quot;false&quot;&gt;)&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/mathml&gt;"><b>表</b>4 <b>两组心肌损伤指标比较</b><mathml id="82"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mo stretchy="false">(</mo><mover accent="true"><mi>x</mi><mo>¯</mo></mover><mo>±</mo><mi>s</mi><mo stretchy="false">)</mo></mrow></math></mathml></a></li>
                                                <li><a href="#75" data-title="&lt;b&gt;表&lt;/b&gt;5 &lt;b&gt;两组内皮功能指标比较&lt;/b&gt;&lt;mathml id=&quot;83&quot;&gt;&lt;math xmlns=&quot;http://www.w3.org/1998/Math/MathML&quot;&gt;&lt;mrow&gt;&lt;mo stretchy=&quot;false&quot;&gt;(&lt;/mo&gt;&lt;mover accent=&quot;true&quot;&gt;&lt;mi&gt;x&lt;/mi&gt;&lt;mo&gt;&#175;&lt;/mo&gt;&lt;/mover&gt;&lt;mo&gt;&#177;&lt;/mo&gt;&lt;mi&gt;s&lt;/mi&gt;&lt;mo stretchy=&quot;false&quot;&gt;)&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/mathml&gt;"><b>表</b>5 <b>两组内皮功能指标比较</b><mathml id="83"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mo stretchy="false">(</mo><mover accent="true"><mi>x</mi><mo>¯</mo></mover><mo>±</mo><mi>s</mi><mo stretchy="false">)</mo></mrow></math></mathml></a></li>
                                    </ul>
                            </dd>
                                    <dd class="guide">
                                        <h6>
                                            <p><a href="#a_bibliography">参考文献</a> </p>
                                        </h6>
                                    </dd>

            </dl>
        </div>
        <!--sidebar end-->
        &nbsp;
        <!--此处有一空格符 勿删-->
    </div>

                <div class="sidebar-b three-collumn" style="width:0;">
            <div class="refer" style="width: 0;">
                <div class="arrow off" title="参考文献"><span></span></div>
                <div class="js-scrollbox" >
                    
                    <div class="subbox active">
                        <h4>
                            <span class="tit">参考文献</span>
                            <a class="close" href="javascript:void(0)">x</a>
                        </h4>
                        <div class="side-scroller">
                            <ul class="refer-list">
                                <li id="5">


                                    <a id="bibliography_1" title="Bershteǐn LL,Katamadze NO,Andreeva AE,et al.Revascularization or conservative strategy in patients with stable coronary heart disease:a contemporary view[J].Kardiologiia,2014,54(1):64-72." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Revascularization or conservative strategy in patients with stable coronary heart disease:a contemporary view">
                                        <b>[1]</b>
                                        Bershteǐn LL,Katamadze NO,Andreeva AE,et al.Revascularization or conservative strategy in patients with stable coronary heart disease:a contemporary view[J].Kardiologiia,2014,54(1):64-72.
                                    </a>
                                </li>
                                <li id="7">


                                    <a id="bibliography_2" title="陈峰,张顺利,李迎.冠心舒通胶囊联合黛力新治疗冠心病PCI术后心绞痛的疗效观察[J].中西医结合心血管病电子杂志,2015,3(8):91-92,94." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZXJH201508060&amp;v=MDU4OThRS0RIODR2UjRUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnluaFY3N05QelhCWnJHNEg5VE1wNDlEWkk=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[2]</b>
                                        陈峰,张顺利,李迎.冠心舒通胶囊联合黛力新治疗冠心病PCI术后心绞痛的疗效观察[J].中西医结合心血管病电子杂志,2015,3(8):91-92,94.
                                    </a>
                                </li>
                                <li id="9">


                                    <a id="bibliography_3" title="赵文卿.通心络胶囊治疗冠心病PCI术后心绞痛的疗效[J].中西医结合心血管病电子杂志,2015,3(14):5-6." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZXJH201514003&amp;v=MzI3MDVyRzRIOVROcTQ5Rlo0UUtESDg0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1VSN3FmWnVabUZ5bmhWNzdOUHpYQlo=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[3]</b>
                                        赵文卿.通心络胶囊治疗冠心病PCI术后心绞痛的疗效[J].中西医结合心血管病电子杂志,2015,3(14):5-6.
                                    </a>
                                </li>
                                <li id="11">


                                    <a id="bibliography_4" title="中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZHXX200703001&amp;v=MDcyODdUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnluaFY3N05QeVhUZHJHNEh0Yk1ySTlGWllRS0RIODR2UjQ=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[4]</b>
                                        中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206.
                                    </a>
                                </li>
                                <li id="13">


                                    <a id="bibliography_5" title="Taheri-Kharameh Z,Heravi-Karimooi M,Rejeh N,et al.Translation and psychometric testing of the Farsi version of the Seattle angina questionnaire[J].Health Qual Life Outcomes,2017,15(1):234." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SSJD&amp;filename=SSJD4B034354A57EF2130893A717887E3055&amp;v=MTYwNTJSYithQ09OdkZTaVdXcjdKSUZwbWFCdUhZZk9HUWxmQnJMVTA1dEJoeGJ5N3dhMD1OajdCYXJmS0h0TElySXBCRmU0SWVRbzd6aFVUNGpaK09YampxeG85ZnNlWA==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[5]</b>
                                        Taheri-Kharameh Z,Heravi-Karimooi M,Rejeh N,et al.Translation and psychometric testing of the Farsi version of the Seattle angina questionnaire[J].Health Qual Life Outcomes,2017,15(1):234.
                                    </a>
                                </li>
                                <li id="15">


                                    <a id="bibliography_6" title="丁平,王丽军,方学奇.尼可地尔治疗合并2型糖尿病的冠心病患者PCI术后心绞痛的疗效观察[J].中国循证心血管医学杂志,2017,9(9):1080-1082." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=PZXX201709020&amp;v=MTQzNDk5Yk1wbzlIWklRS0RIODR2UjRUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnluaFY3N05OVGZUZHJHNEg=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[6]</b>
                                        丁平,王丽军,方学奇.尼可地尔治疗合并2型糖尿病的冠心病患者PCI术后心绞痛的疗效观察[J].中国循证心血管医学杂志,2017,9(9):1080-1082.
                                    </a>
                                </li>
                                <li id="17">


                                    <a id="bibliography_7" title="齐锋,宋柏奇.经皮冠状动脉介入术后不稳定型心绞痛气虚血瘀型中医临床路径评估[J].时珍国医国药,2016,27(11):2676-2677." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=SZGY201611043&amp;v=MDQxNjg2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm1GeW5oVjc3Tk5qZk1kN0c0SDlmTnJvOUJaNFFLREg4NHZSNFQ=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[7]</b>
                                        齐锋,宋柏奇.经皮冠状动脉介入术后不稳定型心绞痛气虚血瘀型中医临床路径评估[J].时珍国医国药,2016,27(11):2676-2677.
                                    </a>
                                </li>
                                <li id="19">


                                    <a id="bibliography_8" title="谷喆,张倩.研究通心络胶囊改善冠心病PCI术后心绞痛发作临床效果探究[J].中西医结合心血管病电子杂志,2016,4(32):53-54." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZXJH201632043&amp;v=MTk4MzE0TzN6cXFCdEdGckNVUjdxZlp1Wm1GeW5oVjc3TlB6WEJackc0SDlmUHJZOUJaNFFLREg4NHZSNFQ2ajU=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[8]</b>
                                        谷喆,张倩.研究通心络胶囊改善冠心病PCI术后心绞痛发作临床效果探究[J].中西医结合心血管病电子杂志,2016,4(32):53-54.
                                    </a>
                                </li>
                                <li id="21">


                                    <a id="bibliography_9" title="Li RJ,Sun Y,Wang Q,et al.Ultrasound Biomicroscopic Imaging for Interleukin-1 Receptor Antagonist-Inhibiting Atherosclerosis and Markers of Inflammation in Atherosclerotic Development in Apolipoprotein-E Knockout Mice[J].Tex Heart Inst J,2015,42(4):319-326." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Ultrasound biomicroscopic imaging for interleukin-1 receptor antagonist-inhibiting atherosclerosis and markers of inflammation in atherosclerotic development in apolipoprotein-E knockout mice">
                                        <b>[9]</b>
                                        Li RJ,Sun Y,Wang Q,et al.Ultrasound Biomicroscopic Imaging for Interleukin-1 Receptor Antagonist-Inhibiting Atherosclerosis and Markers of Inflammation in Atherosclerotic Development in Apolipoprotein-E Knockout Mice[J].Tex Heart Inst J,2015,42(4):319-326.
                                    </a>
                                </li>
                                <li id="23">


                                    <a id="bibliography_10" title="Lin B,Feng DG,Wang F,et al.MiR-365 participates in coronary atherosclerosis through regulating IL-6[J].Eur Rev Med Pharmacol Sci,2016,20(24):5186-5192." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=MiR-365 participates in coronary atherosclerosis through regulating IL-6">
                                        <b>[10]</b>
                                        Lin B,Feng DG,Wang F,et al.MiR-365 participates in coronary atherosclerosis through regulating IL-6[J].Eur Rev Med Pharmacol Sci,2016,20(24):5186-5192.
                                    </a>
                                </li>
                                <li id="25">


                                    <a id="bibliography_11" title="Tay C,Liu YH,Hosseini H,et al.B-cell-specific depletion of tumour necrosis factor alpha inhibits atherosclerosis development and plaque vulnerability to rupture by reducing cell death and inflammation[J].Cardiovasc Res,2016,111(4):385-397." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=B-cell-specific depletion of tumour necrosis factor alpha inhibits atherosclerosis development and plaque vulnerability to rupture by reducing cell death and inflammation">
                                        <b>[11]</b>
                                        Tay C,Liu YH,Hosseini H,et al.B-cell-specific depletion of tumour necrosis factor alpha inhibits atherosclerosis development and plaque vulnerability to rupture by reducing cell death and inflammation[J].Cardiovasc Res,2016,111(4):385-397.
                                    </a>
                                </li>
                                <li id="27">


                                    <a id="bibliography_12" title="张超.银杏达莫注射液对冠心病不稳定性心绞痛的疗效及其对内皮细胞功能的作用[J].中西医结合心血管病电子杂志,2016,4(20):41." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZXJH201620033&amp;v=MTk1MDk5Zk9yNDlHWjRRS0RIODR2UjRUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnluaFY3N05QelhCWnJHNEg=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[12]</b>
                                        张超.银杏达莫注射液对冠心病不稳定性心绞痛的疗效及其对内皮细胞功能的作用[J].中西医结合心血管病电子杂志,2016,4(20):41.
                                    </a>
                                </li>
                                <li id="29">


                                    <a id="bibliography_13" title="Park WC,Seo I,Kim SH,et al.Association between Resting Heart Rate and Inflammatory Markers (White Blood Cell Count and High-Sensitivity C-Reactive Protein) in Healthy Korean People[J].Korean J Fam Med,2017,38(1):8-13." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Association between Resting Heart Rate and Inflammatory Markers (White Blood Cell Count and High-Sensitivity C-Reactive Protein) in Healthy Korean People">
                                        <b>[13]</b>
                                        Park WC,Seo I,Kim SH,et al.Association between Resting Heart Rate and Inflammatory Markers (White Blood Cell Count and High-Sensitivity C-Reactive Protein) in Healthy Korean People[J].Korean J Fam Med,2017,38(1):8-13.
                                    </a>
                                </li>
                                <li id="31">


                                    <a id="bibliography_14" title="薛宁,李颖,黄桢,等.胸痹3号方治疗痰阻心脉型冠心病PCI术后心绞痛疗效观察[J].中西医结合心脑血管病杂志,2014,12(11):1293-1295." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZYYY201411003&amp;v=MjE4MzJGeW5oVjc3TlB6VFNkN0c0SDlYTnJvOUZaNFFLREg4NHZSNFQ2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm0=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[14]</b>
                                        薛宁,李颖,黄桢,等.胸痹3号方治疗痰阻心脉型冠心病PCI术后心绞痛疗效观察[J].中西医结合心脑血管病杂志,2014,12(11):1293-1295.
                                    </a>
                                </li>
                                <li id="33">


                                    <a id="bibliography_15" title="Izumiya Y,Kojima S,Kojima S,et al.Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris[J].Atherosclerosis,2011,214(2):415-421." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011601330698&amp;v=MjkwODVlWnRGaW5sVXJmSUlWb1FheGM9TmlmT2ZiSzdIdEROcVk5RVorZ1BDblV4b0JNVDZUNFBRSC9pclJkR2VycVFUTW53Wg==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[15]</b>
                                        Izumiya Y,Kojima S,Kojima S,et al.Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris[J].Atherosclerosis,2011,214(2):415-421.
                                    </a>
                                </li>
                                <li id="35">


                                    <a id="bibliography_16" title="He WK,Su Q,Liang JB,et al.The protective effect of nicorandil on cardiomyocyte apoptosis after coronary microembolization by activating Nrf2/HO-1 signaling pathway in rats[J].Biochem Biophys Res Commun,2018,496(4):1296-1301." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJESA8EA5ABFDBBF1C5E2DA3FBD4E5489994&amp;v=MjQ0ODNKM3YwekVKbDllbjFLeW1NUm5rNStQZzJXcUdjd2ZicWRUTE9iQ09OdkZTaVdXcjdKSUZwbWFCdUhZZk9HUWxmQnJMVTA1dEJoeGJ5N3dhMD1OaWZPZmNLd2E2RA==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[16]</b>
                                        He WK,Su Q,Liang JB,et al.The protective effect of nicorandil on cardiomyocyte apoptosis after coronary microembolization by activating Nrf2/HO-1 signaling pathway in rats[J].Biochem Biophys Res Commun,2018,496(4):1296-1301.
                                    </a>
                                </li>
                                <li id="37">


                                    <a id="bibliography_17" title="Wang X,Geng J,Zhu H,et al.Renoprotective effect of nicorandil in patients undergoing percutaneous coronary intervention:a meta-analysis of 4 randomized controlled trials[J].Oncotarget,2018,9(14):11837-11845." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Renoprotective effect of nicorandil in patients undergoing percutaneous coronary intervention:a meta-analysis of 4 randomized controlled trials">
                                        <b>[17]</b>
                                        Wang X,Geng J,Zhu H,et al.Renoprotective effect of nicorandil in patients undergoing percutaneous coronary intervention:a meta-analysis of 4 randomized controlled trials[J].Oncotarget,2018,9(14):11837-11845.
                                    </a>
                                </li>
                                <li id="39">


                                    <a id="bibliography_18" title="Katoh M,Takeda N,Arimoto T,et al.Bevacizumab-Related Microvascular Angina and Its Management with Nicorandil[J].Int Heart J,2017,58(5):803-805." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Bevacizumab-related microvascular angina and its management with nicorandil">
                                        <b>[18]</b>
                                        Katoh M,Takeda N,Arimoto T,et al.Bevacizumab-Related Microvascular Angina and Its Management with Nicorandil[J].Int Heart J,2017,58(5):803-805.
                                    </a>
                                </li>
                                <li id="41">


                                    <a id="bibliography_19" title="Padala SK,Lavelle MP,Sidhu MS,et al.Antianginal Therapy for Stable Ischemic Heart Disease:A Contemporary Review[J].J Cardiovasc Pharmacol Ther,2017,22(6):499-510." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Antianginal therapy for stable ischemic heart disease">
                                        <b>[19]</b>
                                        Padala SK,Lavelle MP,Sidhu MS,et al.Antianginal Therapy for Stable Ischemic Heart Disease:A Contemporary Review[J].J Cardiovasc Pharmacol Ther,2017,22(6):499-510.
                                    </a>
                                </li>
                                <li id="43">


                                    <a id="bibliography_20" title="汪禹希.银杏达莫注射液联合复方丹参滴丸治疗冠心病心绞痛的疗效观察[J].中西医结合心血管病电子杂志,2015,3(17):11." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZXJH201517006&amp;v=MjAzNDBQelhCWnJHNEg5VE5xSTlGWW9RS0RIODR2UjRUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnluaFY3N04=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[20]</b>
                                        汪禹希.银杏达莫注射液联合复方丹参滴丸治疗冠心病心绞痛的疗效观察[J].中西医结合心血管病电子杂志,2015,3(17):11.
                                    </a>
                                </li>
                                <li id="45">


                                    <a id="bibliography_21" title="徐超,彭放,邢杨波,等.复方丹参滴丸与红花注射液治疗心绞痛的效果观察[J].中华中医药学刊,2014,32(11):2814-2816." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZYHS201411089&amp;v=MDI0MzZxQnRHRnJDVVI3cWZadVptRnluaFY3N05QelREZmJHNEg5WE5ybzlOYllRS0RIODR2UjRUNmo1NE8zenE=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[21]</b>
                                        徐超,彭放,邢杨波,等.复方丹参滴丸与红花注射液治疗心绞痛的效果观察[J].中华中医药学刊,2014,32(11):2814-2816.
                                    </a>
                                </li>
                                <li id="47">


                                    <a id="bibliography_22" title="董凤玲.复方丹参滴丸治疗冠心病心绞痛观察[J].中国实用医药,2015,10(21):198-199." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZSSA201521141&amp;v=MjI4NDJDVVI3cWZadVptRnluaFY3N05QejdZYjdHNEg5VE9ybzVCWllRS0RIODR2UjRUNmo1NE8zenFxQnRHRnI=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[22]</b>
                                        董凤玲.复方丹参滴丸治疗冠心病心绞痛观察[J].中国实用医药,2015,10(21):198-199.
                                    </a>
                                </li>
                            </ul>
                            <div style='display: none;' class="zqscroller" >
                                <h4 class="">附加材料</h4>
                                <ul></ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            &nbsp;
            <!--此处有一空格符 勿删-->
        </div>

        
    <div class="content">



        <!--tips start-->
                            <div class="tips">
                    <a href="http://navi.cnki.net/KNavi/JournalDetail?pcode=CJFD&amp;pykm=XXGK" target="_blank">心血管康复医学杂志</a>
                2019,28(05),665-669 DOI:10.3969/j.issn.1008-0074.2019.05.26            </div>
        <!--tips end-->
            <div class="top-title">
                <h1 class="title">
                    <span class="vm"><b>丹参滴丸联合尼可地尔对冠心病</b>PCI<b>术后心绞痛患者的效果</b></span>
                                    </h1>

            </div>
                        <h2>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E9%99%88%E7%83%88%E4%BF%8A&amp;code=42910287&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">陈烈俊</a>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E9%99%88%E4%B8%9C%E6%96%B9&amp;code=25149655&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">陈东方</a>
                </h2>
                    <h2>
                    <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=in&amp;skey=%E6%88%BF%E5%8E%BF%E4%BA%BA%E6%B0%91%E5%8C%BB%E9%99%A2%E5%BF%83%E5%86%85%E7%A7%91&amp;code=0164810&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">房县人民医院心内科</a>
            </h2>

        
<div class="link">
    <a id="aexport" class="icon icon-output"  onclick="" href="javascript:void(0);"><i></i>导出/参考文献</a>
    
    <span class="shareBoard" onmouseover="$('#sharedet').show();$('#this').addClass('shareBoardCUR')" onmouseout="$('#sharedet').hide();$('#this').removeClass('shareBoardCUR')">
        <a class="icon icon-share" href="#"><i></i>分享<em></em></a>
        <ul class="shareHide" id="sharedet" style="display: none;">
            <li><a title="复制链接" class="copy" onclick="" href="#"><i></i>复制链接</a></li>
            <li><a title="分享到新浪微博" class="xl" onclick="" href="javascript:common.ShareAction('xl');"><i></i>新浪微博</a></li>
            <li>
                <a title="分享到微信" class="wx" onclick="" href="#"><i></i>微信扫一扫</a>
                <div class="qrcode"><img src='' alt='' /></div>
            </li>
        </ul>

    </span>
    
    <a id="RefTrack" title="创建引文跟踪" class="icon icon-track" onclick="" href="javascript:void(0);"> <i></i>创建引文跟踪 </a>
    <a id="ashoucang" title="收藏" class="icon icon-favor" onclick="" href="javascript:void(0);"><i></i>收藏</a>
    <a class="icon icon-print" onclick="window.print();" href="javascript:void(0);"><i></i>打印</a>
    
    <!--版本切换 end-->
</div>
                            <div class="data" id="a_abstract">
                <span class="keys">摘<span style="font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;</span>要：</span>
                <p><b>目的</b>:研究丹参滴丸联合尼可地尔治疗冠心病PCI术后心绞痛(PAP)的疗效。<b>方法</b>:2014年1月～2017年12月于我院就诊的PAP患者176例患者被随机均分为尼可地尔组和联合治疗组(接受尼可地尔+复方丹参滴丸),两组均同时接受基础治疗8周。观察比较两组治疗前后西雅图心绞痛量表(SAQ)各维度及总评分、hsCRP、白介素-6(IL-6)、肿瘤坏死因子(TNF)-α、心脏型脂肪酸结合蛋白(H-FABP)、肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白I(cTnI)、内皮素(ET)-1、一氧化氮(NO)和一氧化氮合酶(NOS)水平。<b>结果</b>:与尼可地尔组比较,联合治疗组治疗后SAQ各维度评分及总分[(79.90±8.17)分比(95.13±9.74)分]、血清NO[(62.54±6.30)pg/ml比(82.41±8.24)pg/ml]、NOS[(24.13±2.58)U/ml比(30.19±3.11) U/ml]水平升高更显著,血清hsCRP[(5.96±0.62)mg/L比(3.68±0.37) mg/L]、IL-6[(25.89±2.61)ng/L比(20.89±2.18)ng/L]、TNF-α[(10.01±1.13)pg/ml比(6.97±0.73) pg/ml]、H-FABP[(1.01±0.10)ng/ml比(0.89±0.09)ng/ml]、CK-MB[(14.08±1.42)U/L比(11.54±1.17) U/L]、cTnI[(0.26±0.03)ng/ml比(0.22±0.02)ng/ml]、ET-1[(70.76±7.19)pg/ml比(52.96±5.33) pg/ml]水平降低更显著,<i>P</i>均=0.001。<b>结论</b>:复方丹参滴丸联合尼可地尔治疗冠心病PCI术后心绞痛可显著降低炎性因子水平,保护心肌细胞,减少心肌损伤,缓解心绞痛症状,值得推广。</p>
            </div>
                    <div class="data" id="a_keywords">
                <span class="keys">关键词：</span>
                <p>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E5%86%A0%E5%BF%83%E7%97%85&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">冠心病;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E8%A1%80%E7%AE%A1%E6%88%90%E5%BD%A2%E6%9C%AF%2C%E6%B0%94%E5%9B%8A%2C%E5%86%A0%E7%8A%B6%E5%8A%A8%E8%84%89&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">血管成形术,气囊,冠状动脉;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E5%BF%83%E7%BB%9E%E7%97%9B&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">心绞痛;</a>
                </p>
            </div>
        
        <!--brief start-->
        
            <div class="brief">
                    <p>
                            <b>作者简介：</b>
                                                        <span>
                                    *陈东方,E-mail:63265179@qq.com;
                                </span>
                    </p>
                                    <p><b>收稿日期：</b>2018-04-13</p>

            </div>
                    <h1>Therapeutic effect of Danshen dripping pills combined nicorandil on CHD patients with angina pectoris after PCI</h1>
                    <h2>
                    <span>CHEN Lie-jun</span>
                    <span>CHEN Dong-fang</span>
            </h2>
                    <h2>
                    <span>Department of Cardiology, People&apos;s Hospital of Fang County</span>
            </h2>
                            <div class="data" id="a_abstractEN">
                <span class="keys">Abstract：</span>
                <p><b>Objective</b>: To study therapeutic effect of compound Danshen dripping pills(CSDP) combined nicorandil on patients with coronary heart disease(CHD) and angina pectoris after percutaneous coronary intervention(PAP). <b>Methods</b>: A total of 176 PAP patients treated in our hospital from Jan 2014 to Dec 2017 were randomly and equally divided into nicorandil group and combined treatment group(received nicorandil + CSDP), each group received routine treatment simultaneously for eight weeks. Each dimension score and total score of Seattle angina questionnaire(SAQ), serum levels of hsCRP, interleukin(IL)-6, tumor necrosis factor(TNF)-α, heart type fatty acid binding protein(H-FABP), creatine kinase isoenzyme MB(CK-MB), cardiac troponin I(cTnI), endothelin(ET)-1, nitric oxide(NO) and NO synthase(NOS) were observed and compared between two groups before and after treatment. <b>Results</b>: Compared with nicorandil group after treatment, there were significant rise in each dimension score and total score [(79.90±8.17) scores vs.(95.13±9.74) scores] of SAQ,serum levels of NO[(62.54±6.30)pg/ml vs.(82.41±8.24)pg/ml],NOS[(24.13±2.58)U/ml vs.(30.19±3.11) U/ml],significant reductions in serum levels of hsCRP[(5.96±0.62)mg/L vs.(3.68±0.37) mg/L], IL-6 [(25.89±2.61)ng/L vs.(20.89±2.18)ng/L], TNF-α[(10.01±1.13)pg/ml vs.(6.97±0.73) pg/ml], H-FABP[(1.01±0.10)ng/ml vs.(0.89±0.09)ng/ml], CK-MB[(14.08±1.42)U/L vs.(11.54±1.17) U/L], cTnI[(0.26±0.03)ng/ml vs.(0.22±0.02)ng/ml], ET-1[(70.76±7.19)pg/ml vs.(52.96±5.33) pg/ml]in combined treatment group, <i>P</i>=0.001 all. <b>Conclusion</b>: Compound Danshen dripping pills combined nicorandil can significantly reduce inflammatory factor levels, protect myocardial cells, reduce myocardial injury and relieve angina pectoris symptoms in PAP patients.</p>
            </div>
                    <div class="data" id="a_keywordsEN">
                <span class="keys">Keyword：</span>
                <p>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Coronary%20disease&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Coronary disease;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Angioplasty%2Cballoon%2Ccoronary&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Angioplasty,balloon,coronary;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Angina%20pectoris&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Angina pectoris;</a>
                </p>
            </div>
                    <div class="brief">
                
                    <p>
                            <b>Author：</b>
                                                        <span>
                                    CHEN Dong-fang,E-mail:63265179@qq.com;
                                </span>
                    </p>
                                    <p><b>Received：</b> 2018-04-13</p>
                            </div>


        <!--brief start-->
                        <div class="p1">
                    <p id="49">经皮冠脉介入治疗(PCI)是治疗冠心病心绞痛(CHDAP)的重要手段<citation id="84" type="reference"><link href="5" rel="bibliography" /><sup>[<a class="sup">1</a>]</sup></citation>。资料显示,尽管PCI可快速开通阻塞冠脉,改善冠脉循环,缓解患者痛苦,但因其并未从根本上解除引发CHDAP的病因,且PCI术中操作可损伤血管内皮,术后常易发生支架内再狭窄、再灌注损伤、血管机械性阻塞等不良现象,导致术后心绞痛(Postoperative angina pectoris,PAP)<citation id="85" type="reference"><link href="7" rel="bibliography" /><sup>[<a class="sup">2</a>]</sup></citation>。对于PAP患者的治疗,既往多给予调脂、抗血小板聚集等药物治疗,但难以纠正患者冠脉微循环障碍,收效甚微<citation id="86" type="reference"><link href="9" rel="bibliography" /><sup>[<a class="sup">3</a>]</sup></citation>。我院将复方丹参滴丸、尼可地尔联合应用于冠心病PCI术后心绞痛(下称PAP)患者,以探讨其疗效,总结如下。</p>
                </div>
                <h3 id="50" name="50" class="anchor-tag"><b>1 资料与方法</b></h3>
                <h4 class="anchor-tag" id="51" name="51">1.1 一般资料</h4>
                <div class="p1">
                    <p id="52">选择2014年1月～2017年12月于我院就诊的PAP患者176例纳入本研究,男104例(59.09%),女72例(40.91%);年龄43～81(64.25±6.58)岁;病程10个月～16年(5.69±0.61)年,人体质量指数(BMI)21.09～24.86(22.75±2.38)kg/m<sup>2</sup>;心绞痛程度:轻度48例(27.27%),中度77例(43.75%),重度51例(28.98%);植入支架数1～3(1.28±0.15)个。纳入标准:符合《慢性稳定性心绞痛诊断与治疗指南》<citation id="87" type="reference"><link href="11" rel="bibliography" /><sup>[<a class="sup">4</a>]</sup></citation>诊断标准患者;接受常规治疗7～14d但PAP仍反复发作,且每周发作2次及以上患者;2周内未使用本研究药物患者;知情同意者。排除标准:对本研究药物过敏患者;合并其他炎性疾病患者;自身免疫性疾病者;房室传导阻滞患者;活动性出血或出血体质患者;90d内大手术史或较大外伤患者;脑血管意外患者;恶性肿瘤患者;肝、肾等脏器功能不全患者;合并先天性心脏病、心肌病、风湿性心脏病患者。上述患者依据随机数字表法被随机均分为联合治疗组(88例)和尼可地尔组(88例),两组一般资料差异无统计学意义(<i>P</i>&gt;0.05)。具有可比性。见表1。</p>
                </div>
                <h4 class="anchor-tag" id="53" name="53">1.2 方法</h4>
                <h4 class="anchor-tag" id="54" name="54">1.2.1 尼可地尔组:</h4>
                <div class="p1">
                    <p id="55">给予基础治疗+尼可地尔治疗。基础治疗:硝酸异山梨酯片、阿托伐他丁钙、阿司匹林肠溶片、美托洛尔等。尼可地尔(生产企业:天方药业有限公司;国药准字H41024517;规格:5mg24片)口服,5mg/次,3次/d,4周/1疗程。</p>
                </div>
                <div class="area_img" id="56">
                    <p class="img_tit"><b>表</b>1 <b>两组患者一般资料比较</b> <a class="downexcel" onclick="DownLoadReportExcel(this)">导出到EXCEL</a></p>
                    <p class="img_tit"></p>
                    <p class="img_note"></p>
                    <table id="56" border="1"><tr><td><br /></td><td>联合治疗组<br />(88例)</td><td>尼可地尔组<br />(88例)</td><td><i>χ</i><sup>2</sup>/<i>t</i></td><td><i>P</i></td></tr><tr><td><br />男/女(例)</td><td>50/38</td><td>54/34</td><td>0.374</td><td>0.541</td></tr><tr><td><br />年龄(岁)</td><td>63.97±6.54</td><td>65.28±6.62</td><td>1.321</td><td>0.188</td></tr><tr><td><br />病程(年)</td><td>5.66±0.58</td><td>5.73±0.64</td><td>0.760</td><td>0.448</td></tr><tr><td><br />BMI(kg/m<sup>2</sup>)</td><td>22.71±2.35</td><td>22.79±2.41</td><td>0.223</td><td>0.824</td></tr><tr><td><br />心绞痛程度(轻/中/重)</td><td>23/38/27</td><td>25/39/24</td><td>0.273</td><td>0.873</td></tr><tr><td><br />植入支架数(个)</td><td>1.26±0.14</td><td>1.30±0.17</td><td>1.704</td><td>0.090</td></tr></table>
                    <form name="form" action="/kxreader/Detail/DownloadReportExcel" method="POST" style="display:inline">
                        <input type="hidden" name="hidTable" value="" />
                        <input type="hidden" name="hidFileName" value="" />
                    </form>
                    <p class="img_note"></p>
                    <p class="img_note"></p>
                </div>
                <h4 class="anchor-tag" id="57" name="57">1.2.2 联合治疗组:</h4>
                <div class="p1">
                    <p id="58">给予基础治疗+尼可地尔+复方丹参滴丸治疗。基础治疗+尼可地尔同尼可地尔组。复方丹参滴丸(生产企业:天士力制药集团股份有限公司;国药准字:Z10950111;规格:27mg/粒,150粒/盒)舌下含服,270mg/次,3次/d,4周/1疗程。</p>
                </div>
                <h4 class="anchor-tag" id="59" name="59">1.3 观察指标</h4>
                <div class="p1">
                    <p id="60">观察两组治疗前及治疗8周西雅图心绞痛量表(SAQ)得分;血清超敏C反应蛋白(hsCRP)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)等炎性因子水平;心脏型脂肪酸结合蛋白(H-FABP)、肌酸激酶同功酶(CK-MB)、心肌肌钙蛋白I(cTnI)等心肌损伤指标水平;内皮素-1(ET-1)、一氧化氮(NO)、一氧化氮合酶(NOS)等内皮功能指标水平。心绞痛量表得分依据SAQ<citation id="88" type="reference"><link href="13" rel="bibliography" /><sup>[<a class="sup">5</a>]</sup></citation>进行评价,内容包括心绞痛发作频率、心绞痛稳定、躯体活动受限、疾病认知、治疗满意度等5个维度,得分越高说明患者情况越好。两组均采集空腹静脉血5ml,3000r/min离心15min,取上层血清置于-70℃保存待检。hsCRP以免疫比浊法检测,IL-6、TNF-α、H-FABP、CK-MB、ET-1以酶联免疫吸附法(ELISA)检测;CK-MB、cTnI以免疫投射比浊法检测;ET-1、NO、NOS以双抗体夹心法检测。</p>
                </div>
                <h4 class="anchor-tag" id="61" name="61">1.4 统计学处理</h4>
                <div class="p1">
                    <p id="62">采用SPSS 19.0统计软件进行数据分析,计量资料以均数±标准差<mathml id="80"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mo stretchy="false">(</mo><mover accent="true"><mi>x</mi><mo>¯</mo></mover><mo>±</mo><mi>s</mi><mo stretchy="false">)</mo></mrow></math></mathml>表示,比较采用<i>t</i>检验,计数资料以百分率表示,比较采用<i>χ</i><sup>2</sup>检验。<i>P</i>&lt;0.05为差异有统计学意义。</p>
                </div>
                <h3 id="63" name="63" class="anchor-tag"><b>2 结 果</b></h3>
                <h4 class="anchor-tag" id="64" name="64">2.1 两组SAQ评分比较</h4>
                <div class="p1">
                    <p id="65">治疗前,两组SAQ各维度评分及总分差异无统计学意义(<i>P</i>均&gt;0.05);治疗后,两组SAQ各维度评分及总分均较治疗前显著增加(<i>P</i>均=0.001);治疗后,联合治疗组SAQ各维度评分及总分均显著高于尼可地尔组(<i>P</i>均=0.001)。见表2。</p>
                </div>
                <div class="area_img" id="66">
                    <p class="img_tit"><b>表</b>2 <b>两组</b>SAQ<b>评分比较</b> <a class="downexcel" onclick="DownLoadReportExcel(this)">导出到EXCEL</a></p>
                    <p class="img_tit"></p>
                    <p class="img_note"></p>
                    <table id="66" border="1"><tr><td>SAQ维度</td><td>联合治疗组<br />(88例)</td><td>尼可地尔组<br />(88例)</td><td><i>t</i>/</td><td><i>P</i></td></tr><tr><td><br />心绞痛发作频率(分)</td><td></td><td></td><td></td><td></td></tr><tr><td><br /> 治疗前</td><td>7.26±0.74</td><td>7.24±0.73</td><td>0.181</td><td>0.857</td></tr><tr><td><br /> 治疗后</td><td>12.06±1.24<sup>**△△</sup></td><td>10.07±1.11<sup>**</sup></td><td>11.217</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td>31.182/0.001</td><td>19.983/0.001</td><td></td><td></td></tr><tr><td><br />心绞痛稳定(分)</td><td></td><td></td><td></td><td></td></tr><tr><td><br /> 治疗前</td><td>3.18±0.32</td><td>3.20±0.35</td><td>0.593</td><td>0.554</td></tr><tr><td><br /> 治疗后</td><td>6.52±0.66<sup>**△△</sup></td><td>5.27±0.51<sup>**</sup></td><td>14.056</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td>42.717/0.001</td><td>31.394/0.001</td><td></td><td></td></tr><tr><td><br />躯体活动受限(分)</td><td></td><td></td><td></td><td></td></tr><tr><td><br /> 治疗前</td><td>31.26±3.24</td><td>31.28±3.26</td><td>0.041</td><td>0.968</td></tr><tr><td><br /> 治疗后</td><td>42.86±4.33<sup>**△△</sup></td><td>37.19±3.74<sup>**</sup></td><td>9.296</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td>20.122/0.001</td><td>11.175/0.001</td><td></td><td></td></tr><tr><td><br />疾病认知(分)</td><td></td><td></td><td></td><td></td></tr><tr><td><br /> 治疗前</td><td>8.06±0.82</td><td>8.09±0.84</td><td>0.240</td><td>0.811</td></tr><tr><td><br /> 治疗后</td><td>13.11±1.34<sup>**△△</sup></td><td>10.43±1.11<sup>**</sup></td><td>14.448</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td>30.155/0.001</td><td>15.769/0.001</td><td></td><td></td></tr><tr><td><br />治疗满意度(分)</td><td></td><td></td><td></td><td></td></tr><tr><td><br /> 治疗前</td><td>13.68±1.42</td><td>13.69±1.43</td><td>0.047</td><td>0.963</td></tr><tr><td><br /> 治疗后</td><td>20.58±2.17<sup>**△△</sup></td><td>16.94±1.70<sup>**</sup></td><td>12.387</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td>24.959/0.001</td><td>13.724/0.001</td><td></td><td></td></tr><tr><td><br />总分(分)</td><td></td><td></td><td></td><td></td></tr><tr><td><br /> 治疗前</td><td>63.44±6.54</td><td>63.51±6.61</td><td>0.071</td><td>0.944</td></tr><tr><td><br /> 治疗后</td><td>95.13±9.74<sup>**△△</sup></td><td>79.90±8.17<sup>**</sup></td><td>11.238</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td>25.339/0.001</td><td>14.630/0.001</td><td></td><td></td></tr></table>
                    <form name="form" action="/kxreader/Detail/DownloadReportExcel" method="POST" style="display:inline">
                        <input type="hidden" name="hidTable" value="" />
                        <input type="hidden" name="hidFileName" value="" />
                    </form>
                    <p class="img_note">注:SAQ:西雅图心绞痛量表。与治疗前比较*<i>P</i>&lt;0.05,**<i>P</i>&lt;0.01;与尼可地尔组比较△<i>P</i>&lt;0.05,△△<i>P</i>&lt;0.01。下表同。</p>
                    <p class="img_note"></p>
                </div>
                <h4 class="anchor-tag" id="67" name="67">2.2 两组血清炎性因子水平比较</h4>
                <div class="p1">
                    <p id="68">治疗前,两组血清hsCRP、IL-6、TNF-α水平差异无统计学意义(<i>P</i>均&gt;0.05);治疗后,两组血清hsCRP、IL-6、TNF-α水平均较治疗前显著降低(<i>P</i>均=0.001);治疗后,联合治疗组血清hsCRP、IL-6、TNF-α水平均显著低于尼可地尔组(<i>P</i>均=0.001)。见表3。</p>
                </div>
                <div class="area_img" id="69">
                    <p class="img_tit"><b>表</b>3 <b>两组血清炎性因子水平比较</b><mathml id="81"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mo stretchy="false">(</mo><mover accent="true"><mi>x</mi><mo>¯</mo></mover><mo>±</mo><mi>s</mi><mo stretchy="false">)</mo></mrow></math></mathml> <a class="downexcel" onclick="DownLoadReportExcel(this)">导出到EXCEL</a></p>
                    <p class="img_tit"></p>
                    <p class="img_note"></p>
                    <table id="69" border="1"><tr><td>炎性因子</td><td>联合治疗组<br />(88例)</td><td>尼可地尔组<br />(88例)</td><td><i>t</i></td><td><i>P</i></td></tr><tr><td><br />超敏C反应蛋白(mg/L)</td><td></td><td></td><td></td><td></td></tr><tr><td><br /> 治疗前</td><td>9.87±1.24</td><td>9.85±1.22</td><td>0.108</td><td>0.914</td></tr><tr><td><br /> 治疗后</td><td>3.68±0.37<sup>**△△</sup></td><td>5.96±0.62<sup>**</sup></td><td>29.623</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td>44.873/0.001</td><td>26.665/0.001</td><td></td><td></td></tr><tr><td><br />白介素-6(ng/L)</td><td></td><td></td><td></td><td></td></tr><tr><td><br /> 治疗前</td><td>33.76±3.42</td><td>33.73±3.40</td><td>0.058</td><td>0.954</td></tr><tr><td><br /> 治疗后</td><td>20.89±2.18<sup>**△△</sup></td><td>25.89±2.61<sup>**</sup></td><td>13.793</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td>29.768/0.001</td><td>17.158/0.001</td><td></td><td></td></tr><tr><td><br />肿瘤坏死因子-α(pg/ml)</td><td></td><td></td><td></td><td></td></tr><tr><td><br /> 治疗前</td><td>14.78±1.57</td><td>14.80±1.53</td><td>0.086</td><td>0.932</td></tr><tr><td><br /> 治疗后</td><td>6.97±0.73<sup>**△△</sup></td><td>10.07±1.13<sup>**</sup></td><td>21.617</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td>42.315/0.001</td><td>23.328/0.001</td><td></td><td></td></tr></table>
                    <form name="form" action="/kxreader/Detail/DownloadReportExcel" method="POST" style="display:inline">
                        <input type="hidden" name="hidTable" value="" />
                        <input type="hidden" name="hidFileName" value="" />
                    </form>
                    <p class="img_note"></p>
                    <p class="img_note"></p>
                </div>
                <h4 class="anchor-tag" id="70" name="70">2.3 两组心肌损伤指标比较</h4>
                <div class="p1">
                    <p id="71">治疗前,两组H-FABP、CK-MB、cTnI水平差异无统计学意义(<i>P</i>均&gt;0.05);治疗后,两组H-FABP、CK-MB、cTnI均较治疗前显著降低(<i>P</i>均=0.001);治疗后,联合治疗组H-FABP、CK-MB、cTnI水平均显著低于尼可地尔组(<i>P</i>均=0.001)。见表4。</p>
                </div>
                <div class="area_img" id="72">
                    <p class="img_tit"><b>表</b>4 <b>两组心肌损伤指标比较</b><mathml id="82"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mo stretchy="false">(</mo><mover accent="true"><mi>x</mi><mo>¯</mo></mover><mo>±</mo><mi>s</mi><mo stretchy="false">)</mo></mrow></math></mathml> <a class="downexcel" onclick="DownLoadReportExcel(this)">导出到EXCEL</a></p>
                    <p class="img_tit"></p>
                    <p class="img_note"></p>
                    <table id="72" border="1"><tr><td>炎性因子</td><td>联合治疗组<br />(88例)</td><td>尼可地尔组<br />(88例)</td><td><i>t</i>/</td><td><i>P</i></td></tr><tr><td><br />心脏型脂肪酸结合蛋白(ng/ml)</td><td></td><td></td><td></td><td></td></tr><tr><td><br /> 治疗前</td><td>1.22±0.13</td><td>1.20±0.12</td><td>1.061</td><td>0.290</td></tr><tr><td><br /> 治疗后</td><td>0.89±0.09<sup>**△△</sup></td><td>1.01±0.10<sup>**</sup></td><td>8.367</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td>19.579/0.001</td><td>11.410/0.001</td><td></td><td></td></tr><tr><td><br />肌酸激酶同功酶(U/L)</td><td></td><td></td><td></td><td></td></tr><tr><td><br /> 治疗前</td><td>16.85±1.73</td><td>16.83±1.71</td><td>0.077</td><td>0.939</td></tr><tr><td><br /> 治疗后</td><td>11.54±1.17<sup>**△△</sup></td><td>14.08±1.42<sup>**</sup></td><td>12.950</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td>23.851/0.001</td><td>11.606/0.001</td><td></td><td></td></tr><tr><td><br />心肌肌钙蛋白I(ng/ml)</td><td></td><td></td><td></td><td></td></tr><tr><td><br /> 治疗前</td><td>0.32±0.05</td><td>0.31±0.03</td><td>1.609</td><td>0.110</td></tr><tr><td><br /> 治疗后</td><td>0.22±0.02<sup>**△△</sup></td><td>0.26±0.03<sup>**</sup></td><td>10.407</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td>17.420/0.001</td><td>11.055/0.001</td><td></td><td></td></tr></table>
                    <form name="form" action="/kxreader/Detail/DownloadReportExcel" method="POST" style="display:inline">
                        <input type="hidden" name="hidTable" value="" />
                        <input type="hidden" name="hidFileName" value="" />
                    </form>
                    <p class="img_note"></p>
                    <p class="img_note"></p>
                </div>
                <h4 class="anchor-tag" id="73" name="73">2.4 两组内皮功能指标比较</h4>
                <div class="p1">
                    <p id="74">治疗前,两组ET-1、NO、NOS水平差异无统计学意义(<i>P</i>均&gt;0.05);治疗后,两组ET-1水平较治疗前显著降低,NO、NOS水平均较治疗前显著升高(<i>P</i>均=0.001);治疗后,联合治疗组ET-1水平显著低于尼可地尔组,NO、NOS水平显著高于尼可地尔组(<i>P</i>均=0.001)。见表5。</p>
                </div>
                <div class="area_img" id="75">
                    <p class="img_tit"><b>表</b>5 <b>两组内皮功能指标比较</b><mathml id="83"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mo stretchy="false">(</mo><mover accent="true"><mi>x</mi><mo>¯</mo></mover><mo>±</mo><mi>s</mi><mo stretchy="false">)</mo></mrow></math></mathml> <a class="downexcel" onclick="DownLoadReportExcel(this)">导出到EXCEL</a></p>
                    <p class="img_tit"></p>
                    <p class="img_note"></p>
                    <table id="75" border="1"><tr><td>炎性因子</td><td>时段</td><td>联合治疗组<br />(88例)</td><td>尼可地尔组<br />(88例)</td><td><i>t</i>/</td><td><i>P</i></td></tr><tr><td><br />内皮素-1(pg/ml)</td><td>治疗前</td><td>94.76±9.58</td><td>94.72±9.54</td><td>0.028</td><td>0.978</td></tr><tr><td><br /></td><td>治疗后</td><td>52.96±5.33<sup>**△△</sup></td><td>70.76±7.19<sup>**</sup></td><td>18.657</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td></td><td>35.768/0.001</td><td>18.815/0.001</td><td></td><td></td></tr><tr><td><br />一氧化氮(pg/ml)</td><td>治疗前</td><td>39.98±4.04</td><td>40.08±4.10</td><td>0.163</td><td>0.871</td></tr><tr><td><br /></td><td>治疗后</td><td>82.41±8.24<sup>**△△</sup></td><td>62.54±6.30<sup>**</sup></td><td>17.970</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td></td><td>43.372/0.001</td><td>28.030/0.001</td><td></td><td></td></tr><tr><td><br />一氧化氮合酶(U/ml)</td><td>治疗前</td><td>16.19±1.78</td><td>16.22±1.80</td><td>0.148</td><td>0.882</td></tr><tr><td><br /></td><td>治疗后</td><td>30.19±3.11<sup>**△△</sup></td><td>24.13±2.58<sup>**</sup></td><td>14.068</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td></td><td>36.677/0.001</td><td>23.587/0.001</td><td></td><td></td></tr></table>
                    <form name="form" action="/kxreader/Detail/DownloadReportExcel" method="POST" style="display:inline">
                        <input type="hidden" name="hidTable" value="" />
                        <input type="hidden" name="hidFileName" value="" />
                    </form>
                    <p class="img_note"></p>
                    <p class="img_note"></p>
                </div>
                <h3 id="76" name="76" class="anchor-tag"><b>3 讨 论</b></h3>
                <div class="p1">
                    <p id="77">研究证明,炎性因子及血管内皮损伤是导致PCI术后PAP的重要因素<citation id="89" type="reference"><link href="15" rel="bibliography" /><sup>[<a class="sup">6</a>]</sup></citation>。资料显示,PCI可引发不稳定斑块破裂、脱落,在此过程中,不但生成的微小斑块可导致血管阻塞,还可激活T淋巴细胞及产生大量氧化应激产物,生成hsCRP、TNF-α等炎性因子,引发心肌炎性损伤<citation id="90" type="reference"><link href="17" rel="bibliography" /><sup>[<a class="sup">7</a>]</sup></citation>。研究证明,hsCRP、TNF-α等炎性因子不但参与了不稳定斑块生成及发展的进程,还可促进斑块破裂<citation id="91" type="reference"><link href="19" rel="bibliography" /><sup>[<a class="sup">8</a>]</sup></citation>。CRP合成于肝脏,是全身炎性病变的重要标志物。资料显示,hsCRP和冠脉粥样硬化斑块(CAP)形成关系密切,hsCRP水平越高,CAP生成越快,心血管事件发生率越高<citation id="92" type="reference"><link href="21" rel="bibliography" /><sup>[<a class="sup">9</a>]</sup></citation>。IL-6在机体生理病理变化中具有重要作用。研究发现,IL-6可促进血管平滑肌细胞分裂,加快CAP生长速度,并引发其破裂<citation id="93" type="reference"><link href="23" rel="bibliography" /><sup>[<a class="sup">10</a>]</sup></citation>。TNF-α是单核巨噬细胞产生的生物活性较强,可介导免疫调节及多向性炎性反应的致炎因子。研究证明,TNF-α全程参与CAP的形成过程,促进CAP纤维帽变薄,脂质核心增大,致使其破裂、脱落,导致血管阻塞,引发心绞痛<citation id="94" type="reference"><link href="25" rel="bibliography" /><sup>[<a class="sup">11</a>]</sup></citation>。研究证明,正常情况下,内皮细胞不但能够维持细胞结构、血管紧张度,发挥抗凝、抗纤溶蛋白、抗血小板作用,还可抑制炎性因子聚集、黏附于血管壁<citation id="95" type="reference"><link href="27" rel="bibliography" /><sup>[<a class="sup">12</a>]</sup></citation>。研究发现,不但PCI可导致血管内皮细胞损伤,炎性因子在其损伤进程中也发挥着重要作用<citation id="96" type="reference"><link href="29" rel="bibliography" /><sup>[<a class="sup">13</a>]</sup></citation>。研究证明,TNF-α可促进分泌hsCRP、IL-6等促炎性递质,促进内皮细胞分泌血小板活性因子,引发内皮细胞损伤,促进动脉粥样硬化斑块的发生、发展<citation id="97" type="reference"><link href="31" rel="bibliography" /><sup>[<a class="sup">14</a>]</sup></citation>。</p>
                </div>
                <div class="p1">
                    <p id="78">尼可地尔为硝酸酯类药物,可通过提高鸟苷酸环化酶活性提高环磷酸鸟苷水平,降低细胞内Ca<sup>2+</sup>浓度,松弛血管平滑肌,促进冠脉血流<citation id="98" type="reference"><link href="33" rel="bibliography" /><sup>[<a class="sup">15</a>]</sup></citation>。尼可地尔还可促进细胞K<sup>+</sup>通道开放,超极化细胞膜,抑制Ca<sup>2+</sup>内流,促进外周血管扩张,从而降低心肌氧耗及前后负荷<citation id="99" type="reference"><link href="35" rel="bibliography" /><sup>[<a class="sup">16</a>]</sup></citation>。故尼可地尔可在增加心肌氧供的同时降低其氧耗,缓解心绞痛。尼可地尔可缓解PCI导致的心肌损伤,纠正心室壁异常运动<citation id="100" type="reference"><link href="37" rel="bibliography" /><sup>[<a class="sup">17</a>]</sup></citation>。研究证明,尼可地尔可经K<sup>+</sup>～ATP通道发挥缺血预适应作用,降低缺血导致的心肌损伤<citation id="101" type="reference"><link href="39" rel="bibliography" /><sup>[<a class="sup">18</a>]</sup></citation>。此外,尼可地尔还可靶向针对炎性反应,降低炎性因子水平,避免血管内皮损伤<citation id="102" type="reference"><link href="41" rel="bibliography" /><sup>[<a class="sup">19</a>]</sup></citation>。祖国传统医学将心绞痛纳入“厥心痛”“胸痹”的范畴,是气滞、血瘀、寒凝等多种因素引发,临症多行活血、行气、扶正、化痰等治疗<citation id="103" type="reference"><link href="43" rel="bibliography" /><sup>[<a class="sup">20</a>]</sup></citation>。复方丹参滴丸主要包含丹参、冰片、三七等药物,其中丹参活血化瘀,冰片消肿止痛,三七消肿祛瘀,活血镇痛,三者联合可共奏活血化瘀、气血调达、理气止痛、缓解胸痹心痛之功<citation id="104" type="reference"><link href="45" rel="bibliography" /><sup>[<a class="sup">21</a>]</sup></citation>。研究证明,复方丹参滴丸可促进冠脉扩张,保护内皮细胞,改善微循环,降低心肌氧耗,提高心功能,解除心绞痛<citation id="105" type="reference"><link href="47" rel="bibliography" /><sup>[<a class="sup">22</a>]</sup></citation>。在本研究中,治疗后两组SAQ评分、炎性因子、心肌损伤指标、内皮功能指标均显著改善,且联合治疗组改善程度显著优于尼可地尔组,提示与尼可地尔治疗PAP相比较,复方丹参滴丸联合尼可地尔更具优势。</p>
                </div>
                <div class="p1">
                    <p id="79">总之,复方丹参滴丸联合尼可地尔治疗PAP患者,可有效降低炎性因子,避免内皮功能损伤,保护心肌细胞,减少心肌损伤,缓解心绞痛,值得临床推广应用。</p>
                </div>

        <!--brief end-->
        
        <!--conten left  end-->
        <!--增强附件-->
        

        <!--reference start-->
            <div class="reference anchor-tag" id="a_bibliography">
                    <h3>参考文献</h3>
                                        <p id="5">
                            <a id="bibliography_1" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Revascularization or conservative strategy in patients with stable coronary heart disease:a contemporary view">

                                <b>[1]</b>Bershteǐn LL,Katamadze NO,Andreeva AE,et al.Revascularization or conservative strategy in patients with stable coronary heart disease:a contemporary view[J].Kardiologiia,2014,54(1):64-72.
                            </a>
                        </p>
                        <p id="7">
                            <a id="bibliography_2" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZXJH201508060&amp;v=MjQ4NThRS0RIODR2UjRUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnluaFY3N05QelhCWnJHNEg5VE1wNDlEWkk=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[2]</b>陈峰,张顺利,李迎.冠心舒通胶囊联合黛力新治疗冠心病PCI术后心绞痛的疗效观察[J].中西医结合心血管病电子杂志,2015,3(8):91-92,94.
                            </a>
                        </p>
                        <p id="9">
                            <a id="bibliography_3" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZXJH201514003&amp;v=MjEwODg2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm1GeW5oVjc3TlB6WEJackc0SDlUTnE0OUZaNFFLREg4NHZSNFQ=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[3]</b>赵文卿.通心络胶囊治疗冠心病PCI术后心绞痛的疗效[J].中西医结合心血管病电子杂志,2015,3(14):5-6.
                            </a>
                        </p>
                        <p id="11">
                            <a id="bibliography_4" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZHXX200703001&amp;v=MjMwNDc0SHRiTXJJOUZaWVFLREg4NHZSNFQ2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm1GeW5oVjc3TlB5WFRkckc=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[4]</b>中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206.
                            </a>
                        </p>
                        <p id="13">
                            <a id="bibliography_5" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SSJD&amp;filename=SSJD4B034354A57EF2130893A717887E3055&amp;v=MDM2MDlRbzd6aFVUNGpaK09YampxeG85ZnNlWFJiK2FDT052RlNpV1dyN0pJRnBtYUJ1SFlmT0dRbGZCckxVMDV0Qmh4Ynk3d2EwPU5qN0JhcmZLSHRMSXJJcEJGZTRJZQ==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[5]</b>Taheri-Kharameh Z,Heravi-Karimooi M,Rejeh N,et al.Translation and psychometric testing of the Farsi version of the Seattle angina questionnaire[J].Health Qual Life Outcomes,2017,15(1):234.
                            </a>
                        </p>
                        <p id="15">
                            <a id="bibliography_6" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=PZXX201709020&amp;v=MTQ0NjVyRzRIOWJNcG85SFpJUUtESDg0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1VSN3FmWnVabUZ5bmhWNzdOTlRmVGQ=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[6]</b>丁平,王丽军,方学奇.尼可地尔治疗合并2型糖尿病的冠心病患者PCI术后心绞痛的疗效观察[J].中国循证心血管医学杂志,2017,9(9):1080-1082.
                            </a>
                        </p>
                        <p id="17">
                            <a id="bibliography_7" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=SZGY201611043&amp;v=MTE4NzJGeW5oVjc3Tk5qZk1kN0c0SDlmTnJvOUJaNFFLREg4NHZSNFQ2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm0=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[7]</b>齐锋,宋柏奇.经皮冠状动脉介入术后不稳定型心绞痛气虚血瘀型中医临床路径评估[J].时珍国医国药,2016,27(11):2676-2677.
                            </a>
                        </p>
                        <p id="19">
                            <a id="bibliography_8" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZXJH201632043&amp;v=MjExNjZxZlp1Wm1GeW5oVjc3TlB6WEJackc0SDlmUHJZOUJaNFFLREg4NHZSNFQ2ajU0TzN6cXFCdEdGckNVUjc=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[8]</b>谷喆,张倩.研究通心络胶囊改善冠心病PCI术后心绞痛发作临床效果探究[J].中西医结合心血管病电子杂志,2016,4(32):53-54.
                            </a>
                        </p>
                        <p id="21">
                            <a id="bibliography_9" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Ultrasound biomicroscopic imaging for interleukin-1 receptor antagonist-inhibiting atherosclerosis and markers of inflammation in atherosclerotic development in apolipoprotein-E knockout mice">

                                <b>[9]</b>Li RJ,Sun Y,Wang Q,et al.Ultrasound Biomicroscopic Imaging for Interleukin-1 Receptor Antagonist-Inhibiting Atherosclerosis and Markers of Inflammation in Atherosclerotic Development in Apolipoprotein-E Knockout Mice[J].Tex Heart Inst J,2015,42(4):319-326.
                            </a>
                        </p>
                        <p id="23">
                            <a id="bibliography_10" target="_blank" href="http://scholar.cnki.net/result.aspx?q=MiR-365 participates in coronary atherosclerosis through regulating IL-6">

                                <b>[10]</b>Lin B,Feng DG,Wang F,et al.MiR-365 participates in coronary atherosclerosis through regulating IL-6[J].Eur Rev Med Pharmacol Sci,2016,20(24):5186-5192.
                            </a>
                        </p>
                        <p id="25">
                            <a id="bibliography_11" target="_blank" href="http://scholar.cnki.net/result.aspx?q=B-cell-specific depletion of tumour necrosis factor alpha inhibits atherosclerosis development and plaque vulnerability to rupture by reducing cell death and inflammation">

                                <b>[11]</b>Tay C,Liu YH,Hosseini H,et al.B-cell-specific depletion of tumour necrosis factor alpha inhibits atherosclerosis development and plaque vulnerability to rupture by reducing cell death and inflammation[J].Cardiovasc Res,2016,111(4):385-397.
                            </a>
                        </p>
                        <p id="27">
                            <a id="bibliography_12" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZXJH201620033&amp;v=MjU3MTlHRnJDVVI3cWZadVptRnluaFY3N05QelhCWnJHNEg5Zk9yNDlHWjRRS0RIODR2UjRUNmo1NE8zenFxQnQ=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[12]</b>张超.银杏达莫注射液对冠心病不稳定性心绞痛的疗效及其对内皮细胞功能的作用[J].中西医结合心血管病电子杂志,2016,4(20):41.
                            </a>
                        </p>
                        <p id="29">
                            <a id="bibliography_13" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Association between Resting Heart Rate and Inflammatory Markers (White Blood Cell Count and High-Sensitivity C-Reactive Protein) in Healthy Korean People">

                                <b>[13]</b>Park WC,Seo I,Kim SH,et al.Association between Resting Heart Rate and Inflammatory Markers (White Blood Cell Count and High-Sensitivity C-Reactive Protein) in Healthy Korean People[J].Korean J Fam Med,2017,38(1):8-13.
                            </a>
                        </p>
                        <p id="31">
                            <a id="bibliography_14" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZYYY201411003&amp;v=MTY4MTc0UUtESDg0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1VSN3FmWnVabUZ5bmhWNzdOUHpUU2Q3RzRIOVhOcm85Rlo=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[14]</b>薛宁,李颖,黄桢,等.胸痹3号方治疗痰阻心脉型冠心病PCI术后心绞痛疗效观察[J].中西医结合心脑血管病杂志,2014,12(11):1293-1295.
                            </a>
                        </p>
                        <p id="33">
                            <a id="bibliography_15" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13011601330698&amp;v=MDE1OTBNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSVZvUWF4Yz1OaWZPZmJLN0h0RE5xWTlFWitnUENuVXhvQg==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[15]</b>Izumiya Y,Kojima S,Kojima S,et al.Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris[J].Atherosclerosis,2011,214(2):415-421.
                            </a>
                        </p>
                        <p id="35">
                            <a id="bibliography_16" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJESA8EA5ABFDBBF1C5E2DA3FBD4E5489994&amp;v=MTAzMDB3YTA9TmlmT2ZjS3dhNkRKM3YwekVKbDllbjFLeW1NUm5rNStQZzJXcUdjd2ZicWRUTE9iQ09OdkZTaVdXcjdKSUZwbWFCdUhZZk9HUWxmQnJMVTA1dEJoeGJ5Nw==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[16]</b>He WK,Su Q,Liang JB,et al.The protective effect of nicorandil on cardiomyocyte apoptosis after coronary microembolization by activating Nrf2/HO-1 signaling pathway in rats[J].Biochem Biophys Res Commun,2018,496(4):1296-1301.
                            </a>
                        </p>
                        <p id="37">
                            <a id="bibliography_17" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Renoprotective effect of nicorandil in patients undergoing percutaneous coronary intervention:a meta-analysis of 4 randomized controlled trials">

                                <b>[17]</b>Wang X,Geng J,Zhu H,et al.Renoprotective effect of nicorandil in patients undergoing percutaneous coronary intervention:a meta-analysis of 4 randomized controlled trials[J].Oncotarget,2018,9(14):11837-11845.
                            </a>
                        </p>
                        <p id="39">
                            <a id="bibliography_18" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Bevacizumab-related microvascular angina and its management with nicorandil">

                                <b>[18]</b>Katoh M,Takeda N,Arimoto T,et al.Bevacizumab-Related Microvascular Angina and Its Management with Nicorandil[J].Int Heart J,2017,58(5):803-805.
                            </a>
                        </p>
                        <p id="41">
                            <a id="bibliography_19" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Antianginal therapy for stable ischemic heart disease">

                                <b>[19]</b>Padala SK,Lavelle MP,Sidhu MS,et al.Antianginal Therapy for Stable Ischemic Heart Disease:A Contemporary Review[J].J Cardiovasc Pharmacol Ther,2017,22(6):499-510.
                            </a>
                        </p>
                        <p id="43">
                            <a id="bibliography_20" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZXJH201517006&amp;v=MDk5NDRSN3FmWnVabUZ5bmhWNzdOUHpYQlpyRzRIOVROcUk5RllvUUtESDg0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1U=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[20]</b>汪禹希.银杏达莫注射液联合复方丹参滴丸治疗冠心病心绞痛的疗效观察[J].中西医结合心血管病电子杂志,2015,3(17):11.
                            </a>
                        </p>
                        <p id="45">
                            <a id="bibliography_21" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZYHS201411089&amp;v=MDg4NzZWNzdOUHpURGZiRzRIOVhOcm85TmJZUUtESDg0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1VSN3FmWnVabUZ5bmg=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[21]</b>徐超,彭放,邢杨波,等.复方丹参滴丸与红花注射液治疗心绞痛的效果观察[J].中华中医药学刊,2014,32(11):2814-2816.
                            </a>
                        </p>
                        <p id="47">
                            <a id="bibliography_22" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZSSA201521141&amp;v=MDU5Mjl1Wm1GeW5oVjc3TlB6N1liN0c0SDlUT3JvNUJaWVFLREg4NHZSNFQ2ajU0TzN6cXFCdEdGckNVUjdxZlo=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[22]</b>董凤玲.复方丹参滴丸治疗冠心病心绞痛观察[J].中国实用医药,2015,10(21):198-199.
                            </a>
                        </p>
            </div>
        <!--reference end-->
        <!--footnote start-->
        <!--footnote end-->



    </div>

        <input id="fileid" type="hidden" value="XXGK201905026" />
        <input id="dpi" type="hidden" value="200" />
    </div>

<script>
var _hmt = _hmt || [];
(function() {
  var hm = document.createElement("script");
  hm.src = "https://hm.baidu.com/hm.js?6e967eb120601ea41b9d312166416aa6";
  var s = document.getElementsByTagName("script")[0];
  s.parentNode.insertBefore(hm, s);
})();
</script>


    


<input id="hid_uid" name="hid_uid" type="hidden" value="WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" />
<input id="hid_kLogin_headerUrl" name="hid_kLogin_headerUrl" type="hidden" value="/KLogin/Request/GetKHeader.ashx%3Fcallback%3D%3F" />
<input id="hid_kLogin_footerUrl" name="hid_kLogin_footerUrl" type="hidden" value="/KLogin/Request/GetKFooter.ashx%3Fcallback%3D%3F" />
<div class="btn-link" style="display: none"><a target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=XXGK201905026&amp;v=MTc4ODJYTVpiRzRIOWpNcW85SFlvUUtESDg0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1VSN3FmWnVabUZ5bmhWNzdOUFQ=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">知网节</a></div>
<div class="popflow" id="popupTips" style="display: none;">
    <div class="popflowArr"></div>
    <div class="popflowCot">
        <div class="hd"><a href="javascript:void(0);" onclick="$('#popupTips').hide();$('#popupmsg').html('')" class="close">X</a></div>
        <div class="bd">
            <p class="mes" id="popupmsg" name="popupmsg"></p>
          
        </div>
    </div>
</div>
<input type="hidden" id="myexport" value="//kns.cnki.net" />

<input type="hidden" id="KPCAPIPATH" value="//ishufang.cnki.net" />
<input type="hidden" id="CitedTimes" value="" />
<div class="link" id="GLSearch" style="display: none;">
    <i class="icon-trangle"></i>
    <div class="inner">
        <a class="icon" id="copytext">复制</a>
        <a class="icon" target="_blank" onclick="searchCRFD(this)">工具书搜索</a>
    </div>
</div>




<input id="hidVirtualPath" name="hidVirtualPath" type="hidden" value="/kxreader" />
<script src="/kxreader/bundles/detail?v=842_VlRz_g1CMCLi-M0twVw-4EOFG_noWyi_OsMnrAg1"></script>

<script src="/kxreader/Scripts/layer.min.js" type="text/javascript"></script>

<div id="footerBox" class="rootw footer">
</div>
<script>
    if (typeof FlushLogin == 'function') {
        FlushLogin();
    }
    modifyEcpHeader(true);
</script>

<!--图片放大功能 start-->
<script src="/kxreader/bundles/imagebox?v=W4phPu9SNkGcuPeJclikuVE3PpRyIW_gnfjm_19nynI1"></script>

<script type="text/javascript">
    $(function () {
        var j = $.noConflict();
        j(function () {
            j(".zoom-in,.btn-zoomin").imgbox({
                'alignment': 'center',
                'allowMultiple': false,
                'overlayShow': true
            });
        })
    });
</script>
<!--图片放大功能 end-->
<div class="fixedbar">
    <div class="backtop hiddenV" id="backtop">
        <a id="backTopSide" href="javascript:scroll(0,0);" title=""></a>
    </div>
</div>
<script type="text/javascript" src="/kxreader/Scripts/MathJax-2.6-latest/MathJax.js?config=MML_HTMLorMML-full"></script>


    <link href="/kxreader/Content/css/LeftDetail?v=vAscMyvIPP9NePnbGPkqJ0A5tHOvnzl65tGuRDsf9xg1" rel="stylesheet"/>

</body>
</html>

